Companies/Aurinia Pharmaceuticals Inc.

Company profile

Aurinia Pharmaceuticals Inc.

NASDAQ: AUPH · Healthcare · Biotechnology

Canadian filerHQ Edmonton, BCCIK 0001600620Reports USD

#252 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

77B+

FH 92DQ 62GM 69SS 69

v0.1 · 65/100 weight · provisional

↑ net margin, return on assets · ↓ growth stability, disclosure history

Methodology →

Revenue TTM

$298.3M

Rev growth YoY (TTM)

+20.6%

Net income (FY)

$287.2M

Employees

130

Market cap

$2.0B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$283.1M$283.1M2025

Net income$287.2M$287.2M2025

Operating income$104.9M$104.9M2025

Total assets$751.6M$751.6M2025

Liabilities$170.3M$170.3M2025

Equity$581.3M$581.3M2025

Revenue trend

FY2024 – FY2025 · USD

$50.3M

FY24

$57.2M

FY24

$67.8M

FY24

$235.1M

FY24

$62.5M

FY25

$70.0M

FY25

$73.5M

FY25

$283.1M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product96%

License, Collaboration and Royalty Revenue4%

By geography

UNITED STATES93%

JAPAN7%

The read

Aurinia Pharmaceuticals Inc. booked $283.1M in FY2025 revenue, growing 285% year over year — faster than 91% of Healthcare companies we track, at a 101.5% net margin.

Peers · Healthcare

Butterfly Network, Inc.61C GeneDx Holdings Corp.64C Pulse Biosciences, Inc.43D Sionna Therapeutics, Inc.——

Key facts

CEOKevin C. Tang

SectorHealthcare

IndustryBiotechnology

HeadquartersEdmonton, BC

ExchangeNASDAQ: AUPH

Employees130

IPO date2014-09-03

Latest filings

8-K2026-06-04 8-K2026-05-11 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-21 8-K2026-04-03 8-K2026-03-23 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.